Episode Details
Back to Episodes
Corvus Pharma CEO Richard Miller fields follow-up questions about last week's atopic dermatitis data for the ITK inhibitor soquelitinib
Published 7 months, 2 weeks ago
Description
He discusses learnings about durability, dosing, biomarkers, and more for this first-in-class target.